Our Businesses

Regulated Markets

CANADA EUROPE SOUTH AFRICA AUSTRALIA UK SAUDI ARABIA MIDDLE EAST BRAZIL USA

Fourrts is a well-respected, quality-focused contract manufacturing facility for customers in USA, United Kingdom, Europe, Australia, Canada, and other SRA countries.

Fourrts Plant II is a state-of-the-art US FDA/UK MHRA/EU GMP-approved facility with desktop approval from Canada and TGA Australia. We offer contract manufacturing services and formulation development.

Current production capacity is 4 billion tablets and 350 million capsules. The site is equipped with 6 granulation suites, 6 compression lines, 4 coating sections, and 9 packaging lines (7 blisters, 1 bottle and 1 Sachet). The site is also capable of manufacturing pellet-based products, as Granulation Suite 3 is equipped with both top and bottom spray FBE.

The state-of-the-art in-house Research and Development Lab—a miniature production facility—is supported by a dedicated team of scientists who are experienced in both product development and tech transfer.

Fourrts holds UK Market Authorization for Metformin F/c Tabs 500/850 mg; Ibuprofen F/c Tabs 200/400/600 mg; Paracetamol Tabs/Caps 500 mg; Propranolol Tabs 10/40 mg; Atenolol Tabs 25/50/100 mg; and Furosemide Tabs 20/40 mg. Working extensively on the pipeline of many in-house products for Europe and other SRA markets.

What we are looking for

  • CMO/CDMO opportunities for USA, UK, Canada, Europe, Australia, LATAM, South Africa, Brazil, Middle East and others
  • Product Development and Manufacturing for SRA Countries.
  • Co-development of pharmaceutical formulations with business partners for products going off-patent
  • In-Licensing and Out Licensing Opportunities

For more information on plant – Click Here

Reach out for your business requirements:

Mr. K.S. VASU

Chief Executive – Finance & Business Development

Call

+91 98401 38611

(Ext- 303)

Mail